Small molecule-based PD-1 pathway blockade for Human cancer therapy: Tumor suppressor Menin (MEN1), responsible for multiple endocrine neoplasia type 1 syndrome, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 22/February/2017, 9.33 pm

Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of BTG2 and promotes apoptosis, inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 21/February/2017, 11.16 pm
February 21, 2017
Molecular therapy for Bone disorders: Resistin, a pro-inflammatory cytokine, inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via down-regulation of its target gene, 22/February/2017, 9.43 am
February 22, 2017
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

price-50[easy_payment currency=”USD”]

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapy: Tumor suppressor Menin (MEN1), responsible for multiple endocrine neoplasia type 1 syndrome, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.


Research Findings

This study suggests a small molecule-based therapy for human cancers. A therapeutic mix encompassing Menin (MEN1) activatorsby inhibiting the activity of Glycogen synthase kinase 3-β, it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing Menin (MEN1) activators or their analogues may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed information: How does BMP2 (Bone Morphogenetic Protein-2) suppress the expression of PD-1 to promote anti-tumor immunity?

# Research cooperation

For purchase and payment information, you may reach us at admin@genomediscovery.org


References:

Citation: Boominathan, L.,  Small molecule-based PD-1 pathway blockade for Human cancer therapy: Tumor suppressor Menin (MEN1), responsible for multiple endocrine neoplasia type 1 syndrome, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 22/February/2017, 9.34 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.